Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Daratumumab Monotherapy for Patients with Intermediate or High-Risk Smoldering Multiple Myeloma (SMM): Centaurus, a Randomized, Open-Label, Multicenter Phase 2 Study

Blood (2017) 130 (Supplement 1): 510.

https://doi.org/10.1182/blood.V130.Suppl_1.510.510

Published: 2017

Journal Articles

Primary Plasma Cell Leukemia Has a Poor Prognosis Even in the Era of Novel Agents - a Multicenter Case Series

Chezi Ganzel, Ory Rouvio, MD, Hila Magen, MD, Osnat Jarchowsky, Irit Avivi, MD, Katrin Herzog, Cohen Yossi, Tamar Tadmor, MD, Netanel A Horowitz, MD, Merav Leiba, MD, Arnon Nagler, MD MSc, Yael Cohen, MD, Shlomo Bulvik, MD, Dina Ben Yehuda, MD, Jacob M. Rowe, MD, Moshe E. Gatt, MD

Blood (2016) 128 (22): 5699.

https://doi.org/10.1182/blood.V128.22.5699.5699

Published: 2016

Journal Articles

Treatment Patterns and Clinical Outcomes in High-Risk Multiple Myeloma Patients Carrying the 17p Deletion: A Multi-Center Retrospective Observational Study

Yael Cohen, MD, Moshe E. Gatt, MD, Noa Lavi, MD, Chezi Ganzel, Hila Magen, MD, Irit Avivi, MD, Tamar Tadmor, MD, Celia Suriu, MD, Osnat Jarchowsky Dolberg, Amitai Papushado, MD, Svetlana Trestman, MD, Ron Ram, MD

Blood (2016) 128 (22): 4510.

https://doi.org/10.1182/blood.V128.22.4510.4510

Published: 2016

Journal Articles

The natural history of refractory idiopathic thrombocytopenic purpura

Benjamin Djulbegovic, Yael Cohen

Blood (2001) 98 (7): 2282–2283.

https://doi.org/10.1182/blood.V98.7.2282

Published: 2001

Journal Articles

Extensive Venous and Arterial Thrombosis Associated With an Inhibitor to Activated Protein C

Ariella Zivelin, Sanford Gitel, John H. Griffin, Xiao Xu, Jose A. Fernandez, Uri Martinowitz, Yael Cohen, Hillel Halkin, Uri Seligsohn, Aida Inbal

Blood (1999) 94 (3): 895–901.

https://doi.org/10.1182/blood.V94.3.895.415k01_895_901

Published: 1999

NARROW

Daratumumab Monotherapy for Patients with Intermediate or High-Risk Smoldering Multiple Myeloma (SMM): Centaurus, a Randomized, Open-Label, Multicenter Phase 2 Study

Primary Plasma Cell Leukemia Has a Poor Prognosis Even in the Era of Novel Agents - a Multicenter Case Series

Treatment Patterns and Clinical Outcomes in High-Risk Multiple Myeloma Patients Carrying the 17p Deletion: A Multi-Center Retrospective Observational Study

The natural history of refractory idiopathic thrombocytopenic purpura

Extensive Venous and Arterial Thrombosis Associated With an Inhibitor to Activated Protein C

Email alerts

ASH Publications

American Society of Hematology

Daratumumab Monotherapy for Patients with Intermediate or High-Risk Smoldering Multiple Myeloma (SMM): Centaurus, a Randomized, Open-Label, Multicenter Phase 2 Study

Primary Plasma Cell Leukemia Has a Poor Prognosis Even in the Era of Novel Agents - a Multicenter Case Series

Treatment Patterns and Clinical Outcomes in High-Risk Multiple Myeloma Patients Carrying the 17p Deletion: A Multi-Center Retrospective Observational Study

The natural history of refractory idiopathic thrombocytopenic purpura

Extensive Venous and Arterial Thrombosis Associated With an Inhibitor to Activated Protein C

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only